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ABSTRACT

SHORT-TERM SECOND SMOKE EXPOSURE PREDIPOSES HE LUNG
TO INFLMMATION, ELASTIC FIBER INJURY, AND PULMONARY
EMPHYSEMA
George Gu

To determine whether cigarette smoke exposure predisposes lungs to secondary
injury, our laboratory developed a hamster model using lipopolysaccharide (LPS) to
induce pulmonary inflammation following exposure to second-hand smoke. With this
model, inflammatory effects of LPS on smoke-exposed hamsters was measured by
various morphological and biochemical parameters. Additional experiments studied the
effects of exogenous ET-1 and BQ123, which modulate the adherence of inflammatory
cells to lung capillary endothelium. Total bronchoalveolar lavage fluid (BALF)
leukocytes, percent BALF neutrophils, and elastin-specific desmosine and isodesmosine
(DID) crosslinks (free and peptide-bound) in BALF and whole lungs were measured 24
hours (hrs) after LPS treatment. Morphometric changes were evaluated with the mean
linear intercept (MLI) method which measures airspace enlargement, and a disease index
was used to quantify the thickness of interstitial walls and the intensity of inflammatory
infiltrates 24 hrs post-LPS treatment. Animals treated with smoke and LPS showed a
significant increase in BALF neutrophils (15.0% vs 5.1%, respectively) and free lung
DID (359 vs 93.1 ng/mg wet lung) compared to the room-air/LPS group. There was also
a significant increase in the disease index in the smoke/LPS group compared to room
air/LPS controls (1.6 vs 0.9 respectively). As a measure of irreversible lung injury, MLI
was significantly elevated in the smoke/LPS group compared to room air/LPS controls

(83.6 vs 55.7 um, respectively). Conversely, animals treated with BQ123 before
smoke/LPS administration showed a significant decrease in BALF neutrophils compared
to smoke/LPS alone (8.5% vs 15.8% respectively). While BALF neutrophils were
significantly increased in room air-exposed animals given ET-1 compared to room air
alone (13.9% vs 5.2%, respectively), the addition of ET-1 to animals given smoke and/or
LPS had anti-inflammatory effects, suggesting ET-1 counteracts the proinflammatory
activity of these other agents. The results of these studies demonstrate that the
combination of cigarette smoke and secondary inflammation induced by LPS causes
severe acute lung injury that degrades lung elastic fibers and enlarges airspaces.
Treatment with BQ123 reduced this inflammatory process, suggesting it may have a
therapeutic role in reducing the risk of lung damage in smokers with pneumonia or other
types of secondary injury.

ACKNOWLEDGMENTS
I would like to thank my mentor, Dr. Cantor, for allowing me to be part of his lab,
as this project would not be possible without his help. I would also like to thank all of the
committee members for being part of my thesis defense. I would like to thank the Dept.
of Pharmaceutical Sciences for allowing me to be their graduate student and supporting
my efforts in my research.
I owe my deepest gratitude to my family and friends for being supportive of my
efforts. I want to also thank the Department of Environmental Health and Safety, Dr.
Greaney, Suzette, and Jason, for their support in allowing me to pursue my degree.
Without them, I would not be here. Lastly, I would like to thank Shadi Mehraban for
helping and guiding me with the experiments and being supportive.

ii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS.................................................................................... ii
LIST OF FIGURES................................................................................................. vi
CHAPTER 1: INTRODUCTION............................................................................. 1
1.1 Cigarette and Secondhand Smoke…....................................................... 1
1.2 Secondhand Smoking and Bacterial Infections....................................... 2
1.3 Emphysema – COPD……………........................................................... 3
1.4 Neutrophils and Cigarette Smoke…........................................................ 4
1.5 Lipopolysaccharides…............................................................................ 5
1.6 Endothelin-1 and Cigarette Smoke…...................................................... 6
1.7 Endothelin Antagonists and BQ-123…................................................... 7
1.8 Desmosine and Isodesmosine….............................................................. 8
1.9 Experimental Design…........................................................................... 9
1.10 Possible Outcomes from Experiments…............................................... 13
1.11 Summation…......................................................................................... 13
1.12 Objectives, Hypotheses, Specific Aims…............................................. 14
1.12.1 Objectives……………………………………………............14
1.12.2 Hypotheses…………………………...……………………...14
1.12.3 Specific Aims…………………………...…………………...15
CHAPTER 2: MATERIALS AND METHODS....................................................... 18
2.1 Material and Methods.............................................................................. 18
2.1.1 Cigarette Source….................................................................... 18
2.1.2 Animals……………………………………………………….19
2.2 Experimental Design……………...………………………..................... 19
2.2.1 Preliminary Model…................................................................ 19
2.2.2 Model 1 – LPS…...................................................................... 20
2.2.3 Model 2 – BQ-123…................................................................ 20
2.2.4 Model 3 – ET-1 …………........................................................ 20
2.2.5 Model 4 – BQ-123, ET-1, and LPS…...................................... 21
2.3 Extraction of Bronchoalveolar Lavage Fluid and Lung Samples ........... 21
2.4 Microscopic Studies…............................................................................. 22
iii

2.4.1 Histological Evaluation of the Lungs…................................... 22
2.4.2 Hematoxylin and Eosin Staining (H&E) …............................. 23
2.4.3 Mean Linear intercept of the Lung Airspace Diameter............ 24
2.5 Analysis of BALF…............................................................................... 25
2.6 Measurement of BALF Isodesmosine and Desmosine…........................ 25
2.7 Chemotaxis Assay…................................................................................ 27
2.8 Statistical Analysis…............................................................................... 28
CHAPTER 3: RESULTS........................................................................................... 29
3.1 Model 1 – The effect of smoke of LPS-induced
Inflammation.................................................................................................. 29
3.2 Model 2 – The effect of BQ-123 on smoke-enhanced LPS
Inflammation…………...…………………………………….…………….. 39
3.3 Model 3 – The effect of ET-1 on smoke-enhanced
Inflammation………………………………………………...…………....... 42
3.4 Model 4 – The effect of ET-1 and BQ-123 on smoked-enhanced LPS
inflammation………………………………...……………...….…………... 45
3.5 Chemotaxis Assay…................................................................................ 51
3.6 Mean Linear Intercept….......................................................................... 53
3.7 Free Lung Desmosine….......................................................................... 55
CHAPTER 4: DISCUSSIONS.................................................................................. 57
4.1 Smoke Exposure and Secondhand Smoke Exposure .............................. 57
4.2 Cigarette Smoke and Bacterial Infections …...........................................57
4.3 Management of Smoking and Prevention of Acute Lung Injury………. 58
4.4 Current Treatments for Bacterial Infections…........................................ 59
4.5 LPS causes Accumulation in the Alveolar Wall Capillaries ….............. 59
4.6 Use of Endothelin Receptor Antagonists and Blockage of Endothelin
Receptors…....................................................................................................60
4.7 Exogenous ET-1 can induce neutrophil diapedesis in unsmoked
animals…....................................................................................................... 61
4.8 Exogenous ET-1 may cause vasoconstriction in smoke-induced and LPSinduced, reducing the effects of neutrophils diapedesis…............................ 62
iv

4.9 Exogenous ET-1 may reverse LPS-induced vasodilation, counteracting its
effect on neutrophil diapedesis….................................................................. 63
4.10 Short-term Smoke Exposure and Elastin Breakdown…........................ 64
4.11 Conclusion…......................................................................................... 65
BIBLIOGRAPHY...................................................................................................... 67

v

LIST OF FIGURES
Figure 1 Percent BALF Neutrophils Content in Smoked Only Hamsters…......….. 30
Figure 2 Total BALF Leukocyte Count in Smoked Only Animals………..……… 31
Figure 3 Disease Index of Smoked and Room Air Animals………………………. 32
Figure 4 Room Air and Smoke Lung Histology…………...……………………… 33
Figure 5 Total amount of Free BALF DID in Smoke and Control………………... 34
Figure 6 Total amount of Total BALF DID in Smoke and Control……..………....35
Figure 7 Comparison of BALF Free DID and Total DID………...………………..36
Figure 8 Linear Regression of Percent Neutrophils and Total BALF DID…......… 37
Figure 9 Linear Regression of Percent Neutrophils and Free BALF DID……...….38
Figure 10 BALF Leukocytes for Both LPS and BQ123…...………………...……. 40
Figure 11 BALF Neutrophils for both LPS and BQ123……………...……...……. 41
Figure 12 Total Leukocyte Content for ET-1 with Smoked and Room Air
Animals…………………………………………………………...………………... 43
Figure 13 Percent Neutrophils Content for ET-1 with Smoked and Room Air
Animals………………………………………………………...…………………... 44
Figure 14 Total Leukocyte Content for LPS, ET-1 and BQ-123……………...…... 46
Figure 15 Percent Neutrophil Content for LPS, ET-1 and BQ123………......……. 47
Figure 16 BALF Photomicrographs – BQ-123, ET-1, LPS, and PBS…………….. 48
Figure 17 Disease Index of ET-1, BQ-123, and LPS with Smoked animals……… 49
Figure 18 Lung Histology of BQ-123, ET-1, LPS, and PBS ……………..……..... 50
Figure 19 Chemotaxis Assay……………..……………..……...…….....………… 52
Figure 20 Mean Linear Intercept on Lung Airspace Diameter…………..…......…. 54
Figure 21 Free Lung Desmosine……………..……………….…..……..……..…. 56

vi

CHAPTER 1: INTRODUCTION
1.1 Cigarette and Secondhand Smoke
According to the Center for Disease Control and the US Surgeon General,
tobacco smoking is the leading preventable cause of death in the United States that causes
more than 480,000 deaths each year (United States Department of Health and Human
Services, 2014). Smoking has caused more deaths each year than HIV and illegal drug
use. It has also been well established that smokers are more susceptible to chronic
diseases such as periodontal diseases, hypertension, chronic obstructive pulmonary
disease (COPD), impotence, and osteoporosis. However, smokers are more susceptible to
bacterial infections than are non-smokers and such infections are life-threatening. Both
active smokers and people exposed to secondhand smoke toxins are at increased risk of
bacterial infections. Smoking continues to be a major risk factor without having COPD
because it makes individuals susceptible to bacterial infections such as invasive
pneumococcal disease. This disease involves any infection caused by bacteria called
Streptococcus pneumoniae and has been shown that smoking is the strongest risk factor
for this disease. In secondhand smoking, exposure to it has been associated with an
increased risk of meningococcal disease and it is a significant risk factor for children
attributed to maternal smoking. As such, cigarette smoke can rapidly induce the
production of several inflammatory mediators that recruit inflammatory cells to the lung.
Therefore, even short-term exposure to second-hand smoke might predispose the lung to
secondary injury by other agents. About humans, the model provides an opportunity to
determine the relationship between smoking and lung infection.
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1.2 Secondhand Smoking and Bacterial Infections
Tobacco smoking continues to be a prevalent long-term problem in both the
United States and the world. A global study was created called the Global Burden of
Diseases in which it looked at the major causes and factors of deaths across the world and
smoking was ranked two on the major cause of deaths. The study has stated that more
than 8 million people died prematurely because of smoking in 2017 and 7 million people
died from smoking tobacco alone. Specifically, secondhand smoking is a concurrent issue
as it causes large health impacts (Naghavi et al., 2017). It has been estimated 1.2 million
people died prematurely from secondhand smoke. Since 1964, approximately 2.5 million
nonsmokers have died from health problems caused by exposure to secondhand smoke
(United States Department of Health and Human Services, 2014). When put in
comparison to other causes of death secondhand smoke kills more people than road
accidents globally. Globally, the US is one of the many countries in which smoking is
considered a major cause of death in the nation. According to the CDC, nearly 14 of
every 100 U.S adults aged 18 years or older currently smoke cigarettes. However, there
has been a decline in smoking since 2005 from 21 of every 100 adults to 14 of every 100
adults. With the decline of cigarette use, cigarette smoke-related issues continue to persist
in those individuals and the people who are being exposed unintentionally to cigarette
smoke. This unintentional exposure is called secondhand smoking in which the cigarette
smoke comes from the burning end of the cigarette bud and is breathed out by the
smokers. In recent years, there has been a decrease in the number of nonsmokers being
exposed to secondhand smoke due to the changes in the rules for smoking in public and
indoors. There are also growing changes in the lifestyle where smoking is becoming less
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socially acceptable. It continues to be a problem as it causes numerous health problems in
infants and children, including more frequent and severe asthma attacks, respiratory
infections, and sudden infant death syndrome. Secondhand smoke has been known to
cause lung cancers in adults who have never smoked, and secondhand smoke causes
more than 7,300 lung cancer deaths among U.S non-smokers each year. Primarily, this
laboratory is studying the effects of secondhand smoking and a bacterial infection
stimulated by lipopolysaccharides. It is well known that smokers are more susceptible to
nonsmokers to a wide range of chronic diseases. However, smokers become more
susceptible to multiple bacterial infections than nonsmokers and such infections can be
dangerous.
There are many bacterial infections associated with tobacco smoking such as
nasopharyngeal, respiratory tract infections, bronchitis, and COPD (Bagaitkar et al.,
2008). There are potential mechanisms on why there is an increased susceptibility to
bacterial infections such as tobacco-induced physiological and structural changes in
humans, increase in bacterial virulence, and the dysregulation of the immune function.
These mechanisms are not mutually exclusive, and they can all occur simultaneously
(Bagaitkar et al., 2008). There have been instances where tobacco smoke exposure may
play a direct role in bacterial colonization of the respiratory tract by hindering the
clearance of bacteria. Cigarette smoke may also have physiological and structural
changes in vasculature and respiratory tract such as inducing vasoconstriction of the
peripheral arteries but vasodilation of the cerebral blood vessels.

1.3 Emphysema - COPD
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Pulmonary emphysema is a progressive lung disease that is a categorized form of
COPD. It is often caused by chronic and significant exposure to noxious gases and most
commonly caused by cigarette smoking. There are also possible causes for emphysema
such as biomass fuels and environmental pollutants such as sulfur dioxide and particulate
matter (Pahal P, Avula A, 2020). The manifestations of emphysema are the consequences
of damage to the airways and bronchioles which includes alveolar sacs and the alveoli.
The damage causes abnormal permanent dilation of the airspaces and the destruction of
the alveoli walls due to the proteinases such as elastase (Pahal P, Avula A, 2020). As
elastin is an important component of the extracellular matrix that is required to maintain
the lung parenchyma and small airways, the elastase and anti-elastase imbalances
increase the susceptibility for the lung to be damaged which can lead to airspace
enlargement (Pahal P, Avula A, 2020). This allows to conduct a method called mean
linear intercept on the lung airspace diameter as cigarette smoking and secondhand
smoking can increase your risk of emphysema and COPD (Thurlbeck, 1967). The
measurement of the lung airspace will help us determine whether the combination of
secondhand smoke and a bacterial infection can cause enlarged airspace in the lung.

1.4 Neutrophils and Cigarette Smoke
Neutrophils are the main concern in this experimental model as it is one of the
most abundant types of white blood cells and forms the essential part of the innate
immune system. This becomes important as cigarette smoking has been strongly
associated with multiple respiratory infections such as Streptococcus pneumoniae and
Legionella pneumophila and chronic diseases such as COPD and asthma (Thulborn et al.,
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2019). Neutrophils are an important biomarker as they are the most abundant leukocyte in
the human body and are considered the first line of defense in the innate immune system.
They can destroy invading foreign bodies through phagocytosis and intracellular
degradation. They are also considered mediators of inflammation. These infections and
diseases are often the major cause of mortality across the world. The influx of pulmonary
neutrophils often occurs in response to bacterial infection and a common feature of
chronic inflammatory lung diseases. A theory has been proposed by the American
Thoracic Society that compromised anti-bacterial nature in neutrophils may be a major
cause of increased susceptibility to infectious diseases in smokers (Guzik et al., 2011).

1.5 Lipopolysaccharides
Lipopolysaccharide (LPS) is the major component of the outer membrane of
Gram-negative bacteria. Lipopolysaccharide is localized in the outer layer of the
membrane and is exposed to the cell surface. The general structure of LPS is a
hydrophobic lipid section that is responsible for the toxic properties, a hydrophilic core
polysaccharide chain, and a repeating hydrophilic O-antigenic oligosaccharide side chain
that is specific to the bacterial serotype. The LPS used in the studies is from Escherichia
coli O26:B6 (L8274) sourced from Sigma-Aldrich. The function of LPS is to protect the
bacterium against the action of bile salts and lipophilic antibiotics. LPS are heat-stable
endotoxins and have been recognized as a factor in septic shock in humans and more
generally for inducing a strong immune response in normal mammalian cells. LPS has
been widely used for lung inflammation models to simulate chronic lung diseases such as
COPD and emphysema. Lipid A is the main structure where all the endotoxic activity
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occurs. In our study, LPS is being used to simulate a condition of a secondary lung
infection after a chronic smoker contract a respiratory disease or infection. This is due to
the fact smoking is a factor in increasing the risk for respiratory infections and
exacerbating chronic lung diseases.

1.6 Endothelin-1 and Cigarette Smoke
Endothelin or ET is a family of 21 amino acid peptides that have a wide range and
overlapping functions in the lung and its associated diseases. There are three different
isoforms of endothelin, ET-1, ET-2, and ET-3. ET-1 is one of the most abundant isoforms
and better chartered and the only difference between the three is the number of amino
acids in each one. The lung has the highest levels of ET-1 secreted by endothelium,
smooth muscle, airway epithelium, and a variety of other cells. ET-1 circulates in the
plasma and the normal lung, it localizes to the vascular endothelin, airway, and vascular
smooth muscle cells. There is less ET-1 in the lung epithelium. ET-1 has been implicated
in a long list of lung diseases such as ischemia pulmonary edema, acute respiratory
distress syndrome, sepsis, asthma, chronic obstructive pulmonary disease, pulmonary
fibrosis. ET-1 is not stored in cells, but it is processed and transported through the cell in
vesicles which results in direction secretion toward the smooth muscle, and it allows for
ET-1 to act in a paracrine or autocrine manner. This secretion into the circulation allows
for the ET-1 to act as a hormone (Kowalczyk et al., 2015).
There are currently two distinct human endothelin receptors called endothelin A
(ETA) and endothelin B (ETB) receptors. ETA specifically has a higher affinity for ET-1
and ET-2 and the ETA receptors are in great abundance on the vascular and airway
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smooth muscle of the lung. ETB is found mostly on the lung endothelium and the
clearance of ET-1 is mediated by the ETB receptor primarily in the lung but also in the
kidney and liver. The activation of both receptors causes the ETA on the smooth muscle
cells to constrict while the ETB causes bronchoconstriction (Kowalczyk et al., 2015).
Endothelin-1 is the focus of our experiments as it is an important biomarker for
lung injury and inflammation. Since ET-1 is produced in large amounts in the
endothelium, there are often large amounts of it in the bronchoalveolar lavage fluid and
indicates that there is inflammation or some sort of injury in the lungs. Experimental lung
injury of many different types increases circulating ET-1, BAL ET-1, and lung tissue ET1. These levels are also increased in cases of sepsis, burns, acute lung injury, and acute
respiratory distress syndrome (Kowalczyk et al., 2015).

1.7 Endothelin Antagonists and BQ-123
Since the endothelin family has powerful vasoconstrictor properties, it has been
implicated in the pathogenesis of pulmonary diseases and COPD. These studies allow for
the introduction of endothelin receptor antagonists. Endothelin receptor antagonists are a
type of target therapy used to treat people with pulmonary hypertension and have been
shown to slow the progression of pulmonary hypertension and may reverse some of the
damage to the heart and lungs. This is done by reducing the amount of endothelin in the
blood which would limit the harm of excess endothelin in the body. There are several
different types of antagonists such as BQ-123, FR 139317, TAK-044, and BQ788. Our
focus on our experiments is the use of the cyclic pentapeptide BQ-123. The structure of
BQ-123 is a D-Asp-L-Pro-D-Val-L-Leu-D-Trp- peptide isolated from the Streptomyces
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misakiensis (Ihara et al., 1991). The role of BQ-123 is that it is a potent and selective
antagonist for ETA and it also inhibits ET-1 receptor binding and blocks Ca2+
mobilization, cellular contraction, and MAP kinase activation. The inhibition of ET-1 and
ETA-R using BQ-123 is done by reversing the established contractions to the receptor,
displacing the peptide from it. It has been studied for potential therapeutic effects in
preventative lung injury such as emphysema and COPD (Chen et al., 2010). It can also be
a viable treatment for such diseases, and it may be possible to be used in the treatment of
other chronic diseases such as pulmonary hypertension (Hanasato et al., 1999).

1.8 Desmosine and Isodesmosine
Elastin cross-linking in the lung consists of two amino acids unique to mature
elastin; desmosine and its isomer isodesmosine (DID) which can be used as a biomarker
of smoked induced emphysema and COPD (Luisetti et al., 2008). Specifically, free
desmosine has been used as a measure for smoke-induced damage and COPD.
Desmosine in several matrices such as urine, plasma, and sputum have been used to
determine whether patients have COPD or emphysema (Ma et al., 2011). Liu et al.
reported an increased level of free DID when hamsters were exposed to secondhand
cigarette smoke for 2h/day, 5 days/week for a period of 3 months (Liu et al., 2015).
Another study by Churg et al showed a consistent increase in desmosine and
hydroxyproline, both degradation products of the extracellular matrix, in BALF of
smoke-exposed animals after 6 and 24 hours (Wright et al., 2002).
Improvements have followed when it comes to measuring desmosine such as the
use of quantitative high-performance liquid chromatography with tandem mass
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spectrometry. Generally, the measurement of desmosine is designed for total desmosine
amounts and requires hydrolysis of plasma and urine samples in concentrated HCl to
unbind the biomarkers. Instead, the use of a deuterium labeled internal standard was
added directly to a matrix sample which allows for improved accurate and precise
reading of the free desmosine levels (Miliotis et al., 2013).

1.9 Experimental Design
Our laboratory has created an animal model designed to look at the relationship
between acute exposure to cigarette smoke and secondary lung injury induced by
injecting lipopolysaccharide (LPS) intraperitoneally into hamsters. This is done by using
a TE-10 smoking machine which exposes the hamsters to secondhand cigarette smoke.
The inflammation induced by LPS mimics bacterial pneumonia, which is often worse in
cigarette smokers due to increased sequestration of inflammatory cells in the lung
vascular compartment. The cigarette smoke will expose hamsters to a 3-day regimen of
second-hand smoke inhalation to determine if this procedure is sufficient to recruit
inflammatory cells to the lung, the hamster will be injected intraperitoneally with 0.1ml
of 0.2mg/ml of LPS. In addition to LPS, other agents are being tested which include
BQ123 and exogenous endothelin-1. Exogenous endothelin-1 has been used in our
laboratory which has proven to modulate the adherence of inflammatory cells to
endothelium in the lung capillary network (T. Bhavsar et al., 2008). If BQ123, an FDAapproved drug, is found to inhibit inflammatory cell influx, it may serve as a potential
therapeutic agent for the prevention of lung injury due to cigarette smoke.
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Using this model, we will test our primary hypothesis that short-term exposure to
cigarette smoke predisposes the lung to secondary injury by increasing the inflammatory
response to LPS. Parameters that will be evaluated include histopathological changes in
the lung, cell content in bronchoalveolar lavage fluid (BALF), and the amount of free and
peptide-bound desmosine in BALF. In addition, the effect of LPS on BALF leukocyte
chemotaxis will be tested in vitro.
Our laboratory has previously tested the use of endothelin-1 which caused
preferential recruitment of neutrophils in acute lung inflammation induced by either LPS
or cigarette smoke (T. Bhavsar et al., 2008). When ET-1 was injected into the smokedexposed animals, it caused an increased number of neutrophils in the BALF but a reduced
total number of BALF leukocytes. In our experiment, we hypothesize that injection of
ET-1 increases the neutrophil response in the lung to the combination of both cigarette
smoke and LPS.
Our laboratory has also tested drugs in dealing with inflammation of the lungs,
secondary infections, and possible treatments in COPD. Certain substances such as
phosphoramidon and HJP272 have been tested as viable drugs to block the formation of
inflammatory mediators such as endothelin-1 (Patel et al., 2014). Phosphoramidon is a
known zinc metalloproteinase inhibitor that blocks the formation of ET-1 and it has
shown to be a valuable tool in the study of hypertension, stroke, and diseases of the
kidney (T. M. Bhavsar et al., 2008). It has shown to cause a reduction of acute
inflammation in the LPS-induced lung injury. In our experiments, we tested the viability
of BQ-123 as another drug in the treatment of LPS-induced lung injury. It is a known
ETA receptor antagonist and has been tested to prevent the development of pulmonary
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emphysema in rats. BQ-123 has been proven to prevent the development of cigarette
smoke extract-induced emphysema, block the expression of ETA receptors, and inhibit
pulmonary apoptosis. In our experiments, we hypothesize that BQ-123 can block
endothelin-1 activity to decrease the neutrophil response toward cigarette smoke or the
combination of cigarette smoke and LPS.
To test these hypotheses, hamsters will be exposed to cigarette smoke for 3 days,
and then treated with lipopolysaccharide (LPS) to induce secondary lung injury. It is
anticipated that animals exposed to smoke will have a significantly greater reaction to
LPS than those treated with LPS alone. The relationship between brief (second-hand)
cigarette smoke exposure and lung injury remains unclear. We have studied the effect of
lipopolysaccharide (a proinflammatory mediator present in tobacco) on this process to
determine this relationship. Other agents to be tested include BQ123 and endothelin-1,
which both drugs can modulate the adherence of inflammatory cells to endothelium in the
lung capillary network. If BQ123, an FDA-approved drug, is found to inhibit
inflammatory cell influx, it may serve as a potential therapeutic agent for the prevention
of lung injury due to cigarette smoke.
The first experiment that has been performed was the pilot study on the viability
of intraperitoneal injection of LPS after the hamsters were exposed to cigarette smoke for
2 hours in a period of 3 days. The concentration of the LPS injected into the hamsters
would be 0.2mg in 0.1 ml of saline. This is done to affirm that IP injection of LPS can
simulate the bacterial infection of the lungs after the hamsters were exposed to cigarette
smoke. The low dose of LPS is to confirm that it will not cause any noticeable to the
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hamsters. The purpose of this experiment is to show that short-term exposure to cigarette
smoke can cause inflammation and simulate a bacterial infection in the lungs.
In the second set of experiments, the smoke exposure will be increased to 4 hours
for 3 days from 2 hours. The pilot study allowed us to establish that short-term exposure
caused some inflammation in the lungs. In this experiment, we would look at the
possibility of increasing the exposure time to elicit more inflammation in the lungs and
see if the LPS will cause a higher response.
In the third set of experiments, we added another compound called BQ-123. BQ123 has been proven to be a useful therapeutic agent against inflammation and lung
injury. It can then be tested against cigarette smoke and LPS to see whether it will reduce
the amount of inflammation occurring in the lungs and decrease the number of
leukocytes. The dose of the BQ-123 is 200 ug in 0.1ml of saline. The smoking protocol
has stayed the same to keep the consistency in the previous experiment.
In the fourth set of experiments, ET-1 was used exclusively and no LPS nor BQ123 was used in this experiment. Since ET-1 is a powerful vasoconstrictor, a low dose of
5ug in 0.1 ml of saline is required for this experiment. The rationale of this experiment is
to see whether ET-1 will cause an increase or decrease in inflammation after the hamsters
were exposed to cigarette smoke.
In the fifth set of experiments, ET-1 and BQ-123 were used in this experiment.
These two drugs will be combined with LPS to gauge the inflammatory response. This
would determine whether BQ-123 or ET-1 can decrease the number of leukocytes or
neutrophils arriving in the BALF. We would also be looking at the disease index of the
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group to determine whether these drugs affect the thickness of the interstitium in the
lungs and if these drugs can decrease the thickness.

1.10 Possible Outcomes from Experiments
There are possible outcomes that can be found in these experiments. An outcome
is that the exposure protocol may be too short to cause any major inflammation or
damage to the lung and may not affect them as much as we think. Another outcome is
that the short exposure to cigarette smoke and the addition of LPS may have an increased
effect of inflammation in the lungs and cause slight thickening in the interstitial walls.
In the experiment using BQ-123, the introduction of an antagonist may probably
decrease or increase the immune response towards the LPs and the Cigarette smoke. It is
also possible that the BQ-123 will not affect the immune response as this type of
experiment is not a well-studied treatment method, specifically in the lung.
In experiments including the use of ET-1 and LPS, we might see an increase of
leukocytes and inflammation in the lungs as it is well-known ET-1 is an important
indicator for lung injury in the BALF and as “free ET-1”. Although due to ET-1 being a
powerful vasoconstrictor, it may decrease the number of leukocytes entering the lung to
respond to LPS and cigarette smoke.

1.11 Summation
The effects of acute secondhand smoking and bacterial infections are still unclear.
This model will allow us to observe the effects and allow us to determine the relationship
between secondhand smoking and bacterial infections. In order to simulate such an event,
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our laboratory has created a hamster model that allows us to replicate secondhand
smoking using a smoking machine and injecting LPS to cause a bacterial infection in the
lungs. Compared to previous models, we will be using a minimum amount of LPS and
using other agents to look for therapeutic agents to provide an alternative treatment to
secondhand smoke inhalation and bacterial infections

1.12 Objectives, Hypothesis, Specific Aims
1.12.1 Objectives
From these discussions, the effects of acute cigarette exposure and its damage to
the lungs are not well studied. The discussion that usually occurs when it comes to
smoking tobacco products is usually for chronic damage that occurs in long-term smokers
and those who are exposed to secondhand smoke for a long period. With these studies,
we can look at whether short periods of secondhand smoking can predispose the lung to
secondary injury.
The objective of this study was to explore the effects of short-term secondhand
smoke exposure and the immune response from LPS treatment. This study also looks at a
possible treatment involving an endothelin receptor antagonist, BQ123.
1.12.2 Hypotheses
-

Second-hand smoke can cause short-term inflammation and can enhance
secondary injury caused by LPS.

-

The combination of smoke and LPS may cause damage to lung elastic fibers,
resulting in airspace enlargement.

-

The addition of BQ-123 can reduce the secondary inflammatory activity of LPS.
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-

The addition of ET-1 may increase the secondary inflammatory activity of LPS.

1.12.3 Specific aims
-

To examine the effects of short-term, secondhand cigarette smoke and the effects
of a simulated bacterial infection via LPS in a hamster model on various factors of
inflammation such as lung histology, BAL neutrophils, desmosine levels, and
neutrophil chemotaxis

-

To observe the effects of BQ-123 on LPS and cigarette smoke as a possible
treatment for smoke-related secondary lung injury

-

To evaluate the effects of exogenous ET-1 on lung inflammation induced by
cigarette smoke and LPS.

Aim 1: To test the first hypothesis, we needed to determine the effects of short-term
secondhand cigarette smoke on LPS-induced infiltration of inflammatory cells into the
lungs, the damage on the lung parenchymal, and the elastic fiber injury. These were
evaluated by the following parameters.
a) Total leukocyte count in BALF
b) Percent neutrophil count in BALF
c) Total and free DID content in BALF
d) Average Thickness of interstitial walls
Rationale: The number of leukocytes and neutrophils in the BALF following the
treatment of LPS and secondhand cigarette smoke demonstrates the extent of
inflammation in the lungs that would help us understand the effects of a bacterial
infection in the lungs after being exposed to cigarette smoke. The thickness of the
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interstitial walls in the lung can help us understand the damage caused by both the
cigarette smoke and the LPS. This may help explain the deterioration of lung function
when two inflammatory agents are present in the lung.
Aim 2: To test the second hypothesis, the procedures for the smoke inhalations and
injections are the same. However, we added an additional substance to test the efficacy of
a possible treatment for the damage caused by both the bacterial infection and the
cigarette smoke called BQ-123. It has been used previously in a study to find the efficacy
of inhibiting cigarette smoke-induced endothelin receptor expression in pulmonary
arteries. These were evaluated by the following parameters.
a) Total leukocyte count in BALF
b) Percent neutrophil count in BALF
c) Total and free DID content in BALF
Rationale: The reason for this experiment is to find treatments for cigarette-induced
bacterial infections as smoking increases your risks of bacterial infections such as
tuberculosis and pneumonia. By testing a substance with known properties of decreasing
the damage of cigarette smoke and bacterial infections, we may be able to provide
evidence that BQ-123 can be an effective treatment for such issues.
Aim 3: To test this hypothesis, the procedure for the smoke inhalation is the same but the
procedure for the injections is different. We introduced a standalone substance called
endothelin-1 or ET-1 This will be used to determine whether the introduction of an
inflammatory mediator will increase the recruitment of leukocytes into the lung after
exposure to cigarette smoke.

16

Rationale: The reason for such a treatment is that the lab has previously experimented
with ET-1 to demonstrate that the introduction of ET-1 can causes preferential
recruitment of neutrophils. In this experiment, we want to determine whether the
introduction can reduce the inflammation and recruitment of neutrophils after being
treated with cigarette smoke.
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Chapter 2: Materials and Methods
2.1 Materials and Methods
2.1.1 Cigarette Source
The cigarettes were provided by the Center for Tobacco Reference Products
(CTRP), part of the University of Kentucky, College of Agriculture. The specific
cigarette we used is the 3R4F. The 3R4F Kentucky reference cigarettes have been widely
used as monitor cigarettes for mainstream smoke analysis and in vitro and in vivo
toxicological data of cigarettes and novel tobacco products. The 3R4F product is then
shipped to the CTRP where the cases are placed in plastic bags and stored in a cold room
at approximately 3.3°C and 50-60% relative humidity. This type of cigarette is the ideal
product for the experimental model and has been used in different experiments such as
studies for COPD and secondhand smoking.
These cigarettes will be used in the TE-10 Teague Enterprises smoke machine. It
is a microprocessor-controlled cigarette smoking machine that produces either sidestream or mainstream smoke or a combination of the two from filtered, non-filtered, or
standard size research cigarettes. One to ten cigarettes can be smoked at a time.
Cigarettes are loaded into a magazine where they are automatically pushed into a wheel
and lighted. The cigarettes are puffed according to the FTC method and automatically
ejected after a certain number of puffs. Expended butts are extinguished in water. Smoke
is captured in a chimney and transported to a collecting and mixing chamber for use in
exposure studies. The size of the smoking chamber that the animals will be contained is
28 x 19 x 15in.
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The average total smoke particulates are measured using an AME Volumetric dry
gas meter combined with a timed filter sampler which has a diaphragm pump and a timer.
The air mover is a linear pump with a maximum sample flow rate of 17 LPM. The
outflow from the pump can be connected to a dry gas meter to measure volume sampled.
A 0.45um EMD Millipore filter paper was used to weigh the smoke particles. The filter
paper is first weighed before it is inserted into the in-line filter holder and the meter
number is read before it is activated to vacuum the smoke into the filter paper. After 4
hours, turn off the meter, read the measurement on the meter, and remove the filter and
weight the filter. To calculate the smoke particulate matter, take the difference of the
gravimetric measurements before and after it is read and the weight of the filter paper
before. Then divide the difference of the paper weight by the gravimetric difference. This
is expressed in mg/m3. The average total smoke particulates were 15.7mg/m3 at a SEM of
5.6.
2.1.2 Animals
Female Golden Syrian hamsters, weighing 90-100 grams, were purchased from
Envigo. (Somerset, NJ) were used throughout the study. 2-3 animals were housed per
cage with food and water available ad-libitum for at least 24 hours before any
experimentation. All protocols were approved by St. John’s University Institutional
Animal Care and Use Committee.

2.2 Experimental Design
2.2.1 Preliminary Model
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A preliminary experiment was conducted to check the efficacy of performing an
intraperitoneal injection of LPS to induce inflammation in the lungs. The smoking
procedure is exposing the animals to secondhand cigarette smoke for 2 hours per day for
a period of 3 days. The animals were then injected with 200ug of LPS in 0.1ml saline and
left to rest for 24 hours. They were then euthanized via CO2 asphyxiation.
2.2.2 Model 1 - LPS
In the first experiment, the smoking duration was increased from 2 hours to 4
hours to simulate the effects of acute secondhand smoke. The animals were divided into
two groups, Group 1 was exposed to the smoke chamber and Group 2 was exposed to the
room air in the Animal Care Center. After being exposed to the smoke and left to rest for
24 hours, all the groups will be injected with 200ug of LPS in 0.1ml NaCl solution and
left to rest. They were then euthanized after 24 hours via CO2 asphyxiation.
2.2.3 Model 2 - BQ-123
In the second experiment, the smoking protocol remained the same, but the
injection protocols were modified. We decided to test the efficacy of an antagonist called
BQ-123 to look at it as a possible treatment for smoke-induced emphysema. Group 1 was
exposed to cigarette smoke while group 2 was exposed to room air. After they were
exposed and were left to rest for 24 hours, Group 1 was injected with 200ug of BQ-123 in
0.1ml of saline. The animals were left to rest for 30 minutes and then all groups were
injected again with LPS. They were then euthanized after 24 hours via CO2 asphyxiation.
2.2.4 Model 3 - ET-1
In the third experiment involving ET-1, four groups were created: Group 1 was
exposed to room air, Group 2 was exposed to cigarette smoke, group 3 was exposed to
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smoke and injected with ET-1, and group 4 was exposed to room air and injected with
ET-1. The dose of ET-1 will be 10ug in 0.1ml of saline. They will then be euthanized
after 24 hours via CO2 asphyxiation.
2.2.5 Model 4 – BQ-123, ET-1, and LPS
In the fourth experiment, it involves the use of all three substances. Four groups
were created: Group 1 were exposed to cigarette smoke, injected with BQ123, and then
injected with LPS 30 minutes later; Group 2 were exposed to cigarette smoke, injected
with LPS, and then injected with ET-1 30 minutes later; Group 3 were exposed to
cigarette smoke and injected with LPS; Group 4 were exposed to room air and injected
with PBS. They were all euthanized after 24 hours via CO2 asphyxiation.
A total of 120 animals were used in both sets of experiments. All procedures
involved in these studies were reviewed and approved by the IACUC at St. John’s
University.

2.3 Extraction of Bronchoalveolar Lavage Fluid and Lung Samples
All animals used in this study were euthanized by CO2 asphyxiation. The lower
thoracic area of the animals was cleansed with 70% alcohol and surgically exposed to cut
the diaphragm, ensuring complete lung collapse. An incision was made in the cervical
area and two muscle layers (cleidomastoideus and digastricus) were cut to expose the
trachea. A 16-gauge needle was inserted into the trachea (BD Precision Glide Needle)
attached to a 5ml syringe. BALF was obtained by injecting and withdrawing phosphatebuffered saline (PBS) 3 times at 4ml, 3ml, and 3ml volumes to reach a final amount of
10ml for each animal. The extraction of BALF is done slowly to prevent damage to the
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neutrophils from the suction of the syringe. After lavage, lungs were removed from the
chest and separated from extrapulmonary structures, then stored at -20 degrees Celsius
for further studies. BALF photomicrographs were taken using a Nikon Eclipse Ts2R
inverted research microscope at a magnification of 200x. The software used to take the
photos is a NIS-Elements Viewer.
2.4 Microscopic Studies
2.4.1 Histological Evaluation of the Lungs
After euthanasia, the lungs were fixed using 10% neutral-buffered formalin for 2
hours at a pressure of 20 cm of mercury, then removed from the chest and immersed in a
centrifugal tube filled with formalin for 48 hours. The extrapulmonary structures were
removed from the lungs and the samples were cut into random pieces and placed in
cassettes for histological processing. The process of creating the blocks is done by using
an STP 120 from Thermo Fisher. The machine is programmed to create the blocks by
dipping them in solvents and preservatives. The cassettes were passed through graded
concentrations of ethanol, ranging from 35%, 70%, 95%, and 100%, for 5-minute
intervals, followed by repeated immersion in clean 100% xylene for 15, 25, and 40
minutes. The samples were then sequentially incubated in xylene-paraffin mixture (1:1)
for 1 hour, 100% paraffin for 1 hour, and fresh 100% paraffin for 2 hours. They were
then embedded in blocks of paraffin wax, using a Leica 1160 tissue-embedding machine.
The resulting tissue blocks were stored in a refrigerator before processing with a
microtome. Tissue sections were cut with a standard rotary microtome (American Optical
Company) at a thickness of 5um, placed gently in a water bath at 35 degrees Celsius, then
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placed carefully on a SilaneTM coated slides, and incubated at 55 degrees Celsius
overnight for future analysis.
2.4.2 Hematoxylin and Eosin Staining (H&E)
After the tissue sections were dried of all moisture, they were taken for staining.
The tissue sections were deparaffinized in three changes of xylene for 5 minutes in each
staining jar, then they were rehydrated in decreasing concentrations of ethanol (ETOH)
from 100%, 95%, 70%, and 30% at 2-minute intervals. The sections were then washed in
distilled water for 1 minute and stained with hematoxylin for 10 minutes. They were then
immersed in distilled water for 2 minutes, then in a solution mixture of ammonium
chloride (NH4CL) and ETOH for 1 minute, washed in tap and distilled water for 1 minute
each, and dehydrated in 70% ETOH for 2 minutes. The sections were then counterstained
in eosin solution for 2 minutes and then dehydrated in alcohol as follows: 95% ETOH for
2 minutes and 3 changes of 100% ETOH for 2 minutes each. Finally, sections were
cleared in 3 changes of xylene 2 minutes each mounting with coverslips using Permount.
Following euthanasia, the lungs were fixed in situ for several hours with 10%
neutral-buffered formalin at a pressure of 20cm H2O. The lungs were removed from the
thorax as a single block and fixed in formalin. After removing the extrapulmonary
structures, the lungs were cut into random pieces and processed for histological studies.
The solvents used are xylene, ethanol, formaldehyde, and paraffin. The blocks are then
filled with paraffin after the tissue processor has completed its run. Slide sections were
cut at 0.5um using an American Optical Company Microtome with Accublade microtome
blades. The sections are then placed on a hot water bath and taken in by a SilaneTMcoated slide. The slides are then placed on a heating pad to have the water evaporated
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from the slides. After the slides are dry, the sections are stained in hematoxylin and eosin.
The thickness of the interstitial walls was determined by a score from 1-5. Tissue sections
were graded for injury (inflammatory index), using the following scale based on
previously published criteria: 0 = no reaction in alveolar walls; 1 = diffuse reaction in
alveolar walls, with no thickening of the interstitium; 2 = diffuse presence of
inflammatory cells in alveolar walls with a slight thickening of the interstitium; 3 =
moderate interstitial thickening accompanied by inflammatory cell infiltrates; 4 =
interstitial thickening involving more than half of the microscopic field. Results were
expressed as an average of 25 microscopic fields. This type of scoring has been used
previously to evaluate the interstitial damage to the lung and observe inflammatory cell
infiltrates (Patel et al., 2014). The purpose of such analysis is that exposure to cigarette
smoke and intraperitoneal injection of LPS can increase the thickness of the interstitial
walls and the accumulation of various leukocytes.
2.4.3 Mean Linear Intercept of the Lung Airspace Diameter
Another measurement was conducted on the lung sections by doing the mean
linear intercept of the lung airspace diameters. This was done using ImageJ in which
horizontal lines were displayed across each lung section image. For each line, the points
where the line intersects with an alveolar wall are counted, skipping every other line for a
total of 4 lines per image. After they are counted, divide the measured length of the image
by the average numbers of intersecting points per line. This will give the average distance
between the alveolar walls. The pictures were taken and measured at a magnification of
100x (Thurlbeck, 1967). This measurement was conducted to determine whether the
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combination of second-hand smoke exposure and secondary inflammation in the lung can
cause enlargement of the lung airspace.

2.5 Analysis of BALF
Total leukocyte counts were determined using a hemocytometer (Hausser
Scientific, Horsham, PA) at a magnification of 400x. The BALF was then centrifuged for
3 minutes at 5 shelves, the supernatant was removed and stored at -20 degrees Celsius for
further analysis. Differential cell counts were performed by resuspension of the pellet in
1ml PBS, followed by plating of the cells onto microscope slides with a cytospin
(Shandon Inc., Pittsburgh, USA) for 7 minutes at a speed of 800 rpm. The slides were airdried, fixed in methanol for 2 minutes, treated with Giemsa-Wright stain at a ratio of 3:2,
and a coverslip was added using Cytoseal. At least 200 cells were identified using
standard morphological criteria to determine percent neutrophil in BALF.

2.6 Measurement of BALF Isodesmosine and Desmosine
For measurement of free DID, aliquots of cell-free lavage fluid were concentrated
by evaporation to a volume of 0.5ml and combined with 10% trifluoroacetic acid to
precipitate proteins, which were discarded after centrifugation. The supernatants were
mixed with a solution of butanol, glacial acetic acid, and water (4:1:1), then applied to a
CF1 column to separate the free DID.
To determine total DID, aliquots of cell-free lavage fluid were mixed with 37%
HCl and hydrolyzed at 110°C for 24 hours. The samples were then dried, suspended in
butanol, glacial acetic acid, and water (4:1:1), and filtered through a CF1 column to
isolate DID.
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Separation of the crosslinks was performed on a 2x100mm dC18 column (waters
Corporation, Milford, MA) using 2 mobile phases: (A) 7mM heptafluorobutyric acid
(HFBA) and 5mM ammonium acetate in 80% acetonitrile. Following elution with a
programmed gradient, the crosslinks were analyzed with a TSQ discovery electrospray
tandem mass spectrometer (Thermo Fisher Scientific, Waltham, MA), using selected
reaction monitoring of mass to charge ratio transitions. A d4-labeled desmosine standard
was used to quantify the results.
Another method, utilizing LC-MS-MS, was also used to determine free desmosine
in BALF and whole lungs. The lungs were first weighed and added with an appropriate
volume of ultra-pure water to produce a 1:2 dilution (e.g., 2 mL of water to 2 g of the
lung). The samples were then homogenized using a Brinkmann Homogenizer. 1 mL of
the resultant homogenate was directly aliquoted into a separate tube and fortified with
desmosine-D4. 1 mL of BALF samples were directly aliquoted and fortified with
desmosine-D4.
Both desmosine and desmosine-D4 were extracted from lung and BALF samples
by cationic exchange solid phase extraction (SPE). The cation exchange sorbent serves to
retain desmosine and desmosine-D4. First, 3 mL of 0.1N HCl (pH ~ 1.0) was added to 1
mL BALF or 1 mL of lung homogenate, followed by a vortex and centrifugation for 10
min at 3000 rpm prior to column loading. The SPE cartridges were conditioned with 4
mL of methanol followed by 3 mL of 0.1N HCl. Subsequently, the samples (3 mL of the
pre-added 0.1N HCl and 1 mL of BALF or lung homogenate containing desmosine and
desmosine-D4) were loaded into each designated pre-conditioned column and were
allowed to drip with gravity flow. A series of wash steps were performed on each column
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in the order of 3 mL of 0.1N HCl and 4 mL of methanol. The columns were then allowed
to dry at full vacuum for 30 seconds. Elution of desmosine and desmosine-D4 was
utilized with 3 mL of a solvent prepared fresh as a mixture of 95% methanol and 5%
concentrated ammonium hydroxide. Eluents were evaporated to dryness under vacuum
using a Rotovap, and the residues were reconstituted in 200 μL of a 95:5 mixture of water
and methanol and injected into the chromatographic system.

2.7 Chemotaxis Assay
BALF leukocytes from untreated animals were centrifuged and suspended in
Dulbecco’s culture medium. They were gently mixed to ensure uniformity and placed in
the upper wells of Boyden chambers with a 3 µm pore size membrane (Sigma-Aldrich, St
Louis, MO) and exposed to either LPS or no LPS. The lower wells were filled with
additional media to cover the base of the upper wells. The same volume of media was
used for each well. Additional chambers only contained culture medium in both upper
and lower wells and were used for background measurements. Following incubation at 37
degrees Celsius for 24 hours, the cells were carefully removed from the top side of the
insert. The contents of the lower wells were gently mixed to evenly distribute the cells.
Cell migration through the membrane was determined with a CyQuant® cell assay kit
(Thermo Fisher, Waltham, MA) which uses a fluorescent dye that binds to DNA. The
treated cells were transferred to a 96-well microplate and a combination of fluorescent
dye solution and lysis buffer was added to each well. The samples were incubated at
room temperature for 15 minutes and fluorescence emission was measured with a
fluorescent plate reader using a 480/520 nm filter set.
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2.8 Statistical Analysis
One-way analysis of variance (ANOVA) and Bonferroni post-hoc tests were used
to determine statistically significant differences among three or more treatment groups.
When only two groups were compared, a two-tailed t-test was utilized. A p-value of less
than 0.05 was considered statistically significant. Results were expressed as mean ±
standard error of the mean (SEM).
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CHAPTER 3: RESULTS
3.1 Model 1 – The effect of smoke on LPS-induced Inflammation
Syrian Golden hamsters were exposed to cigarette smoke for 4 hours per day over
a 3-day period, then given IP LPS 24 hours later. Bronchoalveolar lavage was performed
24 hours after LPS administration. As shown in Figure 1, animals treated with smoke and
LPS showed a significant increase in percent BALF neutrophils compared to those given
LPS alone (15.0 vs 5.1 percent, respectively, p<0.01). In contrast, the total BALF
leukocytes did not show a significant difference between the groups (Figure 2). As shown
in Figure 3, animals treated with LPS and smoke had a significantly higher disease index
and showed thicker interstitial walls and more intense neutrophil infiltrates compared to
LPS alone (1.6 vs 0.9, respectively; p<0.05).
BALF DID was also measured 24 hrs after LPS administration. The amount of
free and total BALF desmosine was not significantly greater in the animals treated with
both smoke and LPS compared to those given LPS alone (Fig. 5, Fig. 6). Furthermore,
there was no correlation between percent neutrophils and either total or free BALF
desmosine (Figures 8 and 9). However, as shown in Figure 7, there was a significant
correlation between free BALF desmosine and total BALF desmosine, indicating that
free BALF DID responds to inflammatory injury in the same manner as total BALD DID,
and may act as a surrogate for total BALF DID.
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Figure 1. Percent BALF Neutrophils Content in Smoked Only Hamsters. Graph
showing the percent BALF neutrophil content. The animals were treated with either
smoke or room air, then given IP LPS 24 hours later and euthanized 24 hours after LPS
treatment. The group receiving smoke + LPS had significantly increased BALF
neutrophils compare to the other groups (one-way ANOVA with Bonferroni post-test).
The results were expressed as mean ± SEM (p=0.0003). The numbers under each bar
represent the sample size (N).
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Figure 2. Total BALF Leukocyte Count in Smoked Only Animals. Graph showing the
total BALF leukocyte counts. The animals were treated with either smoke or room air,
then given IP LPS 24 hours later and euthanized one day later. There were no statistically
significant differences among the groups. The results were expressed as mean ± SEM.
The numbers under each bar represent the sample size (N).
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Figure 3. Disease Index of Smoked and Room Air Animals. Graph showing the
disease index of both smoked and control animals. Animals treated with smoke and LPS
had a significantly higher index than those remaining in room air prior to LPS. The
animals were exposed to either smoke or room air, then given IP LPS 24 hours later. The
animals were euthanized 24 hours after LPS treatment. The results were expressed as
mean ± SEM. Statistical analysis was performed with the two-tailed Mann Whitney test
(p=0.0561). The numbers under each bar represent the sample size (N).
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Figure 4. Room Air and Smoke Lung Histology. Photomicrograph of paraffinembedded sections from hamster lungs stained with hematoxylin and eosin. The left
photomicrograph represents the lung of an animal exposed to only room air and injected
with IP LPS. The right photomicrograph represents the lung of an animal exposed to only
cigarette smoke for 4 hours per day for 3 days. The right photograph shows significantly
thicker interstitium walls and more infiltrates compared to the left photograph. The
animals were euthanized 24 hours after IP treatment. The photomicrographs were taken
at 100x magnification.
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Figure 5. Total amount of Free BALF DID in Smoke and Control. Graph showing the total
amount of free BALF DID in both Smoked and Control. There was no significant
difference between the two groups. The animals were exposed to either smoke or room
air, then treated with IP LPS. There was no statistically significant difference between the
groups (two-tailed t-test). The animals were euthanized 24 hours after IP treatment. The
results were expressed as mean ± SEM. The numbers under each bar represent the sample
size (N).
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Figure 6. Total amount of Total BALF DID in Smoke and Control. Graph showing
the total amount of total BALF DID in both Smoked and Control. There was no
significant difference between the two groups. The animals were exposed to either smoke
or room air, then treated with IP LPS. There was no statistically significant difference
between the groups (two-tailed t-test). The animals were euthanized 24 hours after IP
treatment. The results were expressed as mean ± SEM. The numbers under each bar
represent the sample size (N).
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Figure 7. Comparison of BALF Free DID and Total DID. Graph showing significant
correlation between free BALF DID and total BALF DID (r2=0.4728, p<0.01). The
animals were exposed to either smoke or room air, then treated with IP LPS. The animals
were euthanized 24 hours after IP treatment. The results were expressed as a simple
linear regression at 95% confidence level (p=0.0011).
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Figure 8. Linear Regression of Percent Neutrophils and Total BALF DID. Graph
showing the relationship between Total BALF DID and percent BALF neutrophils. There
was no significant correlation between these parameters (r2= 0.02, p<0.05) The animals
were exposed to either smoke or room air, then treated with IP LPS. The results were
expressed as a simple linear regression at 95% confidence level (N of 19 on both X and Y
axis, p=0.5775).
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Figure 9. Linear Regression of Percent Neutrophils and Free BALF DID. Graph
showing the relationship between free BALF DID and percent neutrophils. There was no
significant correlation between these parameters (r2=0.07, p<0.05). The animals were exposed to
either smoke or room air, then treated with IP LPS. The results were expressed as a simple

linear regression at 95% confidence level (N of 19 on both X and Y axis, p=0.2634).
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3.2 Model 2 – The effect of BQ-123 on smoke-enhanced LPS Inflammation
An endothelin receptor inhibitor was utilized to determine the potential role of
endothelin in smoke-enhanced LPS-induced inflammation. As shown in Figure 11, the
hamsters were exposed to cigarette smoke for 4 hours per day over a 3-day period, then
treated with IP BQ123 prior to LPS administration, there was a significant decrease in
percent BALF neutrophils with animals given BQ123 compared to LPS alone. (8.5 vs
15.8 percent, respectively, p<0.05). However, there was no significant difference in the
BALF leukocytes between the groups (Fig. 10).
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Figure 10. BALF Leukocytes for Both LPS and BQ123. Graph showing the total
BALF leukocyte counts. The animals were exposed to smoke and treated 24 hours later
with either IP LPS or IP BQ-123 and IP LPS 30 minutes later. All animals were
euthanized 24 hours after IP treatment. There was no statistically significant difference
between the groups (two-tailed t-test). The results were expressed as mean ± SEM. The
numbers under each bar represent the sample size (N).
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Figure 11. BALF Neutrophils for both LPS and BQ123. Graph showing the percent
neutrophil content. The animals were exposed to smoke and treated 24 hours later with
either IP LPS or IP BQ-123 and IP LPS 30 minutes later. All animals were euthanized 24
hours after IP treatment. There was a statistically significant difference between the
groups (p<0.05; two-tailed t-test). The results were expressed as mean ± SEM
(p=0.0289). The numbers under each bar represent the sample size (N).
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3.3 Model 3 – The effect of ET-1 on smoke-enhanced Inflammation
The use of exogenous administration of ET-1 was utilized to show whether ET-1
can influence the number of neutrophils entering the lungs. The hamsters were exposed to
cigarette smoke for 4 hours per day over a 3-day period, then the animals were treated
with IP ET-1. Another group of hamsters was exposed to room air only, then given IP
ET-1. As shown in Figure 12, total BALF leukocytes were significantly decreased in
smoke exposed animals receiving ET-1 compared to animals only treated with smoke
(23.5 vs 60.4 x 104, p<0.01). There was also a significant decrease in BALF leukocytes in
room air exposed animals given ET-1 compared to those left untreated (26.2 vs 67.0 x
104, p<0.001). As shown in Figure 13, there was a significant increase in percent
neutrophils in the room air/ET-1 group compared to room air only controls (12.5 vs 5.2,
respectively, p<0.01). These findings suggest that ET-1 may preferentially increase
neutrophil migration from the vascular compartment while suppressing overall leukocyte
diapedesis.
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Figure 12. Total Leukocyte Content for ET-1 with Smoked and Room Air Animals.
Graph showing BALF leukocyte content. All animals were exposed to cigarette smoke or
room air prior to the IP injection protocol. The animals were treated with either IP ET-1
or PBS 24 hours post-smoke exposure and euthanized one day later. For both smoke and
room air-exposed animals, ET-1 significantly decreased BALF leukocytes and compared
using one-way ANOVA with Bonferroni post-test. The results were expressed as mean ±
SEM. The numbers under each bar represent the sample size (N). The numbers under
each bar represent the sample size (N).
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Figure 13. Percent Neutrophils Content for ET-1 with Smoked and Room Air
Animals. Graph showing BALF neutrophil content. All animals were exposed to
cigarette smoke or room air prior to the IP injection protocol. The animals were treated
with either IP ET-1 or PBS at 24 hours post-smoke exposure and euthanized one day
later. Both the smoke + ET-1 and ET-1 only groups had significantly increased BALF
neutrophils compared to controls exposed to room air and injected with PBS and
compared using one-way ANOVA with Bonferroni post-test. The results were expressed
as mean ± SEM. The numbers under each bar represent the sample size (N).
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3.4 Model 4 – The effect of ET-1 and BQ-123 on smoke-enhanced LPS Inflammation
Both ET-1 and BQ-123 were used to look at their effect on LPS-enhanced
inflammation in smoke-exposed animals. As shown in Figure 15, there was a significant
increase in percent BALF neutrophils in the Smoke+LPS group compared to room air
controls (9.3 vs 1.5 percent, respectively; p<0.01), which was abrogated by both BQ123
and ET-1. Similarly, as show in Figure 14, there was a significant increase in total BALF
leukocytes in the Smoke+LPS group compared to room air controls, which was reversed
with ET-1 and BQ123 (84.40 vs 19.85 vs 25.95 x 104, respectively; p<0.0001). These
changes in BALF neutrophil populations are shown in Figure 16.
Animals treated with Smoke + LPS and Smoke + LPS + ET-1 had a significantly
higher disease index than room air controls that were not treated with these agents (1.8
and 1.9 vs 0.8, respectively; p<0.0001; Figures 17 and 18). These findings suggest that
ET-1 may cause thickening of the alveolar wall and increases in the disease index,
despite limiting the influx of leukocytes into the lung. Such an effect is possible if ET-1
induced interstitial edema by enhancing vascular permeability.
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Figure 14. Total Leukocyte Content for LPS, ET-1 and BQ-123. Graph showing
BALF leukocyte content. All animals were exposed to cigarette smoke or room air prior,
then given IP injections of either BQ123 or ET-1 at 24 hours post-smoke exposure.
Animals receiving BQ123 were first treated with this agent and then given LPS 30
minutes later. Animals receiving ET-1 were first treated with LPS and then treated with
ET-1 30 minutes later. All animals were euthanized 24 hours after IP treatment. The
group receiving smoke + LPS had significantly increased BALF leukocytes compared to
all other groups using one-way ANOVA with Bonferroni post-test. The results were
expressed as mean ± SEM. The numbers under each bar represent the sample size (N).
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Figure 15. Percent Neutrophil Content for LPS, ET-1 and BQ123. Graph showing
BALF neutrophil content. All animals were exposed to cigarette smoke or room air prior,
then given IP injections of either BQ123 or ET-1 at 24 hours post-smoke exposure.
Animals receiving BQ123 were first treated with this agent and then given LPS 30
minutes later. Animals receiving ET-1 were first treated with LPS and then treated with
ET-1 30 minutes later. All animals were euthanized 24 hours after IP treatment. The
group receiving smoke + LPS had significantly increased BALF neutrophils compared to
the room air + PBS group and compared using one-way ANOVA with Bonferroni posttest. The results were expressed as mean ± SEM. The numbers under each bar represent
the sample size (N).
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Figure 16. BALF Photomicrographs – BQ-123, ET-1, LPS, and PBS.
Photomicrographs showing neutrophil content with animals exposed to BQ-123, LPS,
and ET-1 taken at 200x. On the top left, there is significantly less neutrophils when BQ123 is used compared to LPS. On the top right, there is significantly less neutrophils
when ET-1 is used compared to LPS. The groups involving BQ-123, LPS, and ET-1 were
exposed to smoke and the control was only exposed to room air.
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Figure 17. Disease Index of ET-1, BQ-123, and LPS with Smoked animals. Graph
showing the disease index of LPS, ET-1+LPS, BQ123+LPS and Room Air+PBS.
Animals treated with smoke and treated with IP LPS+ET-1 and LPS had a significantly
higher index than those remaining in room air prior to LPS (p<0.0001). The animals
were exposed to either smoke or room air, then given IP LPS 24 hours later. The animals
were euthanized 24 hours after LPS treatment. Statistical analysis was performed with a
one-way ANOVA test. The results were expressed as mean ± SEM (p<0.0001). The
numbers under each bar represent the sample size (N).
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Figure 18. Lung Histology of BQ-123, ET-1, LPS, and PBS Photomicrographs of
paraffin-embedded slide sections from lungs treated with smoke and injected with either
ET-1, LPS, or BQ-123. Controls were exposed to room air and given PBS which had
thicker interstitial walls and more infiltrates when compared to the control. The
photomicrograph on the top right shows an animal smoked and treated with LPS + ET-1
which had thicker walls and more infiltrates when compared to the control. The animals
were euthanized 24 hours after IP treatment. The photomicrographs were taken at 100x
magnification.
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3.5 Chemotaxis Assay
A Boyden chamber assay was used to measure the chemotactic activity of LPS in
smoked hamsters. As shown in Figure 19, BALF leukocytes from hamsters exposed to
smoke and did not show increased chemotaxis for LPS dissolved in culture media
compared to media alone (72.0 vs 46.8 fluorescence units per 104 cells). Similarly,
BALF leukocytes from room air exposed animals showed no enhancement in chemotaxis
for LPS (83.1 and 39.9 fluorescence units per 104 cells, respectively). These results
suggest that the effect of LPS on leukocyte migration into the lung is not directly related
to the chemotactic activity of LPS but may instead depend on secondary release of
proinflammatory cytokines by vascular endothelium or other lung interstitial cells.
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Figure 19. Chemotaxis Assay. Graph showing the chemotaxis assay results. There was
no significant difference between the animals exposed to smoke and room air. BALF
leukocytes from both smoked and room air animals were exposed to LPS in a Boyden
chamber (chemotaxis) assay. Relative fluorescence emission of leukocytes was measured
at a fluorescent plate reader using a 480/520 nm filter set. Results were expressed as
mean ± SEM. Comparison among groups was done using one-way ANOVA followed by
Bonferroni multiple comparison post-hoc test. The numbers under each bar represent the
sample size (N).
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3.6 Mean Linear Intercept
Measurement of the Mean Linear Intercept was performed 24 hours after LPS
treatment to determine whether short-term exposure to cigarette smoke combined with
secondary inflammation induced by LPS can induce emphysematous changes. As shown
in Figure 20, animals treated with Smoke+LPS had a significantly greater MLI compared
to animals treated with room air and PBS (83.60 vs 55.7 respectively; p<0.0001). These
findings suggest that even brief exposure to second-hand cigarette smoke can result in
irreversible lung damage when associated with pneumonia or other forms of secondary
inflammation.
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Figure 20. Mean Linear Intercept on Lung Airspace Diameter. Graph showing a
significant difference in mean linear intercept on the lung airspace diameter. Animals
treated with Smoke+LPS had a significantly larger airspace compared to animals treated
with room air and PBS. The first group was exposed to smoke for 4 hours per day during
a period of 3 days and injected with IP LPS. The second group was only exposed to room
air and PBS. The animals were then euthanized 24 hours after IP administration. The
numbers under each bar represent the sample size (N)
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3.7 Free Lung Desmosine
Measurements of free lung desmosine were conducted 24 hours after IP LPS
treatment to determine whether the combination of smoke exposure and secondary
inflammation can cause increased elastic fiber injury and if this can be a better biomarker
for elastic fiber damage compared to using free BALF desmosine. As shown in Figure
21, free lung desmosine was significantly higher in the group exposed to Smoke+LPS
compared to the other groups treated with smoke only, room air+LPS, and room air only
(359.1 vs 95.05 vs 93.07 vs 0.000 respectively). This suggests that the combination of
cigarette smoke and LPS acts synergistically regarding elastic fiber injury and that free
lung desmosine may be a better indicator of damage to these fibers than free BALF
desmosine. These results in combination with the MLI measurements support the
hypothesis that short-term cigarette smoke increases the susceptibility of the lung to
severe injury from secondary sources of inflammation such as bacterial infections.
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Figure 21. Free Lung Desmosine. Graph showing significant difference in Free Lung
Desmosine. Animals treated with Smoke+LPS have a significantly higher amount of free
desmosine in the lung compared to the Smoke, Room-Air+LPS, and Room air. The
animals were exposed to either smoke or room air, then given IP LPS or PBS 24 hours
later. The animals were euthanized 24 hours after treatment. Statistical analysis was
performed with one-way ANOVA. The numbers under each bar represent the sample size
(N).
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CHAPTER 4: DISCUSSION
4.1 Smoke Exposure and Secondhand Smoke Exposure
Cigarette smoking and secondhand cigarette smoke exposure continue to be a
major issue in the U.S. According to the CDC and US Surgeon General, tobacco smoking
has contributed to more than 480,000 deaths per year in the United States, including more
than 41,000 deaths resulting from secondhand smoke exposure (United States
Department of Health and Human Services, 2014). Smoking has been known to cause
cancer, heart disease, lung diseases, COPD, emphysema, and chronic bronchitis.
Secondhand smoke has also been a contributing factor in smoke-related deaths as
secondhand exposure can increase the risk of a stroke. In children, exposure to
secondhand smoke increases their risk of ear infections, severe asthma attacks,
respiratory infections, and a greater risk of sudden infant death syndrome. In adults, nonsmokers exposed to secondhand smoke can cause heart disease, lung cancer, and stroke.

4.2 Cigarette Smoke and Bacterial Infections
As it is well known that cigarette smoke can cause a variety of issues, bacterial
infections are one of the most critical problems affecting smokers and nonsmokers.
Active smokers and those exposed to secondhand smoke are at increased risk of bacterial
infections. Cigarette smoke exposure increases the susceptibility to respiratory diseases
and infections in the lung such as tuberculosis and pneumonia. This can cause smokers
and nonsmokers to be more vulnerable to multiple bacterial infections which can be lifethreatening for both active smokers and nonsmokers. They can be exposed to bacteria
such as pneumococcus and meningococcus as they are more commonly occurring
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bacterial infections in both active and second-hand smokers than in nonsmokers.
Lipopolysaccharides (LPS) are used in our experiments to stimulate bacterial infections
such as meningococcus due to it being a gram-negative bacterium capable of producing
endotoxins similar to LPS (Rouphael & Stephens, 2012). Other studies have shown that
cigarette smoke can drastically increase air concentrations of endotoxins with each
inhalation containing 17.4 pmol of endotoxin per smoked cigarette (Larsson et al., 2004).

4.3 Management of Smoking and Prevention of Acute Lung Injury
With cigarette smoke being a major contributor to deaths in the US, there are
methods to stop smoking that can decrease your risk of respiratory diseases and bacterial
infections. The most common is smoking cessation. According to the US Surgeon
General cessation of cigarette smoking is beneficial at any age as it improves health
status and enhances the quality of life. It reduces the risk of many adverse health effects
such as respiratory diseases, COPD, and bacterial infections (United States Department
of Health and Human Services, 2014). Other methods of smoke cessation have been used
such as nicotine replacement therapy or smoke cessation medications (Feldman &
Richards, 2018). There are FDA-approved smoking cessation drugs such as varenicline
and bupropion to prevent you from continuing smoking. There are also more commercial
and common products such as nicotine gum and patches. However, there are little to no
therapeutic agents that have been approved to prevent or reduce acute lung injury. There
are some methods such as aerosolized high dose systemic corticosteroids that can prevent
acute lung injury, but it is still under clinical trial and have been associated with worse
outcomes in patients with sepsis shock (Litell et al., 2011).
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4.4 Current Treatments for Bacterial Infections
Since smoking is one of the main risk factors for respiratory diseases, the
cessation of smoking can decrease the risks of both bacterial infections and respiratory
diseases such as COPD and emphysema. For the treatment of bacterial infections, the use
of antibiotics and sometimes antifungal drugs are used. An example would be the use of
macrolide or tetracycline have been recommended for patients with no risk factors for
drug-resistant Streptococcus pneumoniae (Feldman & Richards, 2018). Bacterial
meningitis is a common infection in both smokers and second-hand smokers with a twoto-fourfold higher risk of getting the infection. The standard treatment for meningitis is
ampicillin as smokers and secondhand smokers are considered immunocompromised by
the CDC (United States Department of Health and Human Services, 2014).

4.5 LPS Causes Sequestration of Neutrophils in the Alveolar Wall Capillaries
Secondhand smoke exposure is well known to cause inflammation in the lungs.
Our results have shown that secondhand smoke exposure and intraperitoneal injection of
LPS causes an increased number of neutrophils in the lungs and increased thickness in
the alveolar walls. In addition, LPS-treated lung tissue saw an increased movement of
neutrophils into the alveolar wall, causing accumulation in the interstitium and alveolar
walls (Figure 4). Other studies have shown that cigarette smoke exposure causes
polymorphonuclear leukocytes, causes an increased number of PMN in the circulation,
and a degree of deterioration in lung function. This type of accumulation can be caused
by the deformability of PMN following smoke exposure which may be a cause in their
retention in the pulmonary capillaries (Terashima et al., 1999).
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In our histology, we saw that LPS can cause diapedesis of the sequestered
neutrophils which then accumulate in the alveoli, contributing to the increased
inflammation and thickness of the interstitium (Figure 4). Animals treated with cigarette
smoke and LPS had a significantly higher disease index compared to the control (Figure
3). There were significantly more infiltrates and thicker interstitium walls indicating that
both cigarette smoke and LPS increased inflammation in the alveolar walls. This occurs
when the inflammatory response goes through a process of reaching the site of
inflammation and moves through the endothelial surface towards the tissue. The
infiltration of activated neutrophils into the lung compartments is one of the indicators in
acute lung injury and acute respiratory distress syndrome. Cigarette smoke has been
known to be associated with an increased incidence of acute respiratory distress
syndrome (Siew et al., 2016). Other studies have shown that the administration of
aerosolized LPS can cause LPS-induced PMN transendothelial migration into the
interstitial space and alveolar airspace. (Basit et al., 2021).

4.6 Use of Endothelin Receptor Antagonists and Blockage of Endothelin Receptors
Endothelin Receptor antagonists (ERAs) play an important role in the treatment
of pulmonary arterial hypertension and have been tested for their protective effects in
different models of acute lung injury (ALI). Our laboratory and other studies have used
ERAs to prevent the development of ALI and ET-1-induced lung edema. In previous
laboratory experiments, Patel et al used a novel endothelin antagonist called HJP272
which resulted in attenuated LPS-induced acute lung injury in hamsters in which HJP272
was able to significantly reduce the number of neutrophils and reduced lung injury. Other
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studies have used nonselective ERAs such as Bosentan and Tezosentan. Chen et al have
used bosentan and other ERAs in determining that ET-1 plays an important role in the
pathogenesis of emphysema. The use of bosentan and BQ123 prevented the development
of cigarette smoke extract-induced emphysema and blocked the expression of the ETA
receptor (Chen et al., 2010).
In our results, we have shown that blocking endogenous ET-1 may counteract the
effects of LPS in the alveolar and inflammatory response with the use of ERAs. In Figure
11, there was a significant decrease in neutrophil content in the group treated with BQ123
compared to a group treated without BQ123. It is also shown in Figure 11 and 15, there
was a significant decrease of neutrophils in a group injected with BQ123 compared to a
group treated only with smoke+LPS. Since BQ-123 is known to be a selective antagonist
for the ETA receptor and can competitively block the receptor, reducing the likelihood of
ET-1 from binding. It is possible that when BQ-123 blocks ETA receptors which
prevents endogenous ET-1 from binding to the receptors which reduce the level of
inflammatory response against LPS and resulting in lower neutrophil counts compared to
the animals treated with LPS or cigarette smoke. Other studies have shown that BQ-123
has protective effects against LPS-induced oxidative stress in the Wistar rat lungs and
concluded that BQ-123 was able to prevent lung edema development and decrease LPSinduced oxidative stress (Piechota et al., 2011). Another study conducted by Sampaio et
al showed that intratracheal instillation of BQ-123 inhibits neutrophil and eosinophil
accumulation in LPS-induced pleurisy (Sampaio et al., 2004).

4.7 Exogenous ET-1 can induce neutrophil diapedesis in unsmoked animals.

61

Our results have shown that external use of ET-1 can cause neutrophils to migrate
towards the lung and sequester into the alveolar walls in animals not treated with either
LPS or smoke. As shown in Figure 12, there was a significantly higher number of
leukocytes in the smoke and room air compared to animals treated with Smoke+ET-1 and
Room Air+ET-1. This indicates that there are possible vasoconstrictions on the airways
and parenchyma that reduce the number of leukocytes entering the lung. A study done by
Admaicaza et al showed that the use of exogenous ET-1 can induce significant changes in
the mechanical properties of the airways and parenchyma in guinea-pig lungs (Adamicza
et al., 2001). In Figure 13, there was a significant increase in neutrophils in groups treated
with ET-1 and cigarette smoke compared to animals exposed to room air and smoke+ET1. This may be due to the fact that many endothelial cells produce endogenous ET-1
which includes leukocytes and macrophages (Kowalczyk et al., 2015). ET-1 also
stimulates the synthesis of TNF-α which further enhances the inflammatory response by
stimulating the chemotaxis and phagocytosis of macrophages, monocytes, and
neutrophils. It is possible that the exogenous ET-1 may cause the neutrophils to
sequester into the lungs due to it being attracted to ET-1 as it is a proinflammatory
mediator. Other studies have shown that ET-1 induces neutrophil recruitment in adaptive
inflammation via TNAF-𝞪 and CXCL1/CXCR2 in mice (Zarpelon et al., 2012).

4.8 Exogenous ET-1 may cause vasoconstriction in smoked-induced and LPSinduced, reducing the effects of neutrophil diapedesis.
Exogenous ET-1 may cause vasoconstriction in smoked-treated animals. Cigarette
smoke has been well known to cause vasoconstriction in the pulmonary system due to
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increased endogenous ET-1 from cigarette smoke exposure. Cigarette smoke can induce
ET-1 synthesis to respond to the smoke-induced inflammation. As shown in Figure 15,
there was a significant increase of neutrophil content in animals treated with smoke+LPS
compared to the group treated with smoke+LPS+ET-1. It is possible that adding
exogenous ET-1 to already existing endogenous ET-1 may cause the blood vessels to
constrict further towards the lungs, resulting in fewer neutrophils in the alveoli. Other
studies have shown that ET-1 levels are elevated in heavy and light smokers and patients
who have COPD and pulmonary hypertension (Lu et al., 2018). They also have shown
that cigarette smoke also elevates ET-1 levels and causes increased expression of ETA
receptors (Milara et al., 2012). With cigarette smoke already increasing the levels of
endogenous ET-1, an additional amount of exogenous ET-1 entering the body can cause
an increased effect on vasoconstricting which can decrease the number of neutrophils
entering the lung.

4.9 Exogenous ET-1 may reverse LPS-induced vasodilation, counteracting its effect
on neutrophil diapedesis.
Exogenous ET-1 may reverse LPS-induced vasodilation in the alveolar walls
which can counteract the effects of neutrophils diapedesis. LPS is known to cause
vasodilation when injected into animals, which increases the inflammatory response of
neutrophils (Farias et al., 2002). Our results have shown that when the animals were
exposed to cigarette smoke and then injected with LPS it increased the number of
leukocytes and neutrophils entering the lung compared to a group treated with
Smoke+LPS+ET-1 (Figure 14, 15). As shown in both Figures 14 and 15, the pretreated
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Smoke+LPS animals were injected with IP exogenous ET-1, the number of leukocytes
and neutrophils significantly decreased compared to the group treated with smoke and
LPS. It is possible that the ET-1 is constricting the blood vessels that are already dilated
from the endotoxin, reducing neutrophil diapedesis. Our results have also indicated that
there is rapid neutrophil turnover in the lungs as the exogenous ET-1 has a vasopressor
effect on the BALF neutrophil counts by lowering the cumulative positive effect of
smoke exposure (Figure 15). It is possible that there are a lower number of BALF
neutrophils due to exogenous ET-1 inducing vasoconstriction in the blood vessels,
resulting in fewer neutrophils in smoke-treated animals. However, the mechanism on
how ET-1 can reverse LPS-induced vasodilation in the alveolar walls is uncertain.

4.10 Short-term Smoke Exposure and Elastin Breakdown
Short-term exposure to second-hand cigarette smoke increased the number of lung
neutrophils but it was not enough to cause significant elastin breakdown. Desmosine and
isodesmosine are used as a biomarker for elastin breakdown and are found in different
matrices such as the lung and the sputum (Luisetti et al., 2008). Our results have shown
that animals exposed for 4 hours daily for a period of 3 days had an increased number of
neutrophils and leukocytes in the lung but there was no significant correlation in elastin
breakdown and percent neutrophils in the BALF. However, there was a correlation
between the free BALF desmosine and total BALF desmosine levels (Figure 7).
As shown in Figure 20, the lung airspace size was measured, and it showed a
significant increase in airspace size compared to the control group. This is consistent with
the increased free lung desmosine as shown in Figure 21. Figure 21 also shows that free
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lung desmosine is a better indicator of lung damage compared to BALF desmosine. In the
group exposed to Smoke+LPS (Fig.21), there was a significantly higher amount of free
desmosine compared to the other groups. This may indicate that the combination of shortterm cigarette smoke and secondary inflammation caused by LPS may cause significant
elastin damage in the lung. Cigarette smoke and LPS appear to interact synergistically
which can result in more damage to the lung. This type of result is similar to patients
diagnosed with emphysema and a common feature of COPD (Wollmer et al., 2014). Our
laboratory has previously shown that smoke-induced elastin breakdown may take 1 to 2
months of exposure. When the animals were exposed to cigarette smoke for 3 months, the
percent lung surface area decreased and the amount of free BALF desmosine increase
significantly during the second month of exposure (Cantor et al., 2018). Other studies
have shown that desmosine can be a reliable biomarker for COPD and pulmonary
emphysema that can be found in urine, plasma, sputum, lung, and BALF matrices.
(Luisetti et al., 2008) (Cantor et al., 2018)

4.11 Conclusion
The results obtained from the cigarette smoke/LPS model suggest that many
secondhand smokers can become increasingly vulnerable to secondary infections that
cause more damage to their lungs. Our results show that acute exposure to cigarette
smoke and simulating a secondary infection using LPS causes enlargement of airspace
size that is irreversible due to elastic fiber degradation and rupture of alveolar walls. The
use of endothelin receptor antagonist may help decrease the inflammatory response and
possibly prevent further acute lung injury, based on our finding that BQ-123, a potent
selective ERA, decreases neutrophil influx into the lung. In contrast, exogenous ET-1
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increased the proportion of BALF neutrophils in animals exposed to room air while
lowering total BALF leukocyte content, consistent with its previously demonstrated
proinflammatory effect on neutrophils. However, in animals pretreated with both smoke
and LPS, exogenous ET-1 showed anti-inflammatory activity, suggesting the possibility
that its vasopressor effect on the capillary bed compromises blood flow to the lung,
thereby reducing leukocyte influx into the lung. Further investigation of the effects of
ET-1, bacterial infections, and ERAs on smoke-related lung injury may lead to more
effective approaches to preventing exacerbation of elastic fiber damage and
emphysematous changes following pneumonia or other types of secondary inflammation.
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